×
About 16,848 results

Melanoma Mortality Rates Fell in 2010s as New Therapies Took Hold
https://www.medscape.com/viewarticle/985492

Dec 13th, 2022 - A new generation of treatments appears to have caused U.S. melanoma mortality rates to plunge between 2013 and 2017 for the first time in 4 decades, a new study finds, although the dip appeared to stabilize over the next 2 years. Dr Navkirat Kahlon "This data is very encouraging and represents the real-world effectiveness of these newer therapies, which include immunotherapies and targeted ther...

Positive Moderna, Merck Cancer Vaccine Data Advances mRNA Promise, Shares Rise
https://www.medscape.com/viewarticle/985512

Dec 13th, 2022 - An experimental cancer vaccine from Moderna Inc based on the messenger RNA (mRNA) technology used in successful COVID-19 vaccines has been shown to work against melanoma, sending Moderna shares more than 20% higher and driving up other biotechs working on similar treatments. A combination of Moderna's personalized cancer vaccine and Merck & Co's blockbuster immunotherapy Keytruda cut the risk o...

Biomarkers and Renal Cell Carcinoma
https://www.medscape.com/viewarticle/968743

Dec 8th, 2022 - This transcript has been edited for clarity. Sumanta Pal, MD: Welcome to Medscape InDiscussion. My name is Monty Pal, and I'm a genitourinary medical oncologist at the City of Hope Comprehensive Cancer Center in Los Angeles. You're in for a real treat today. We're going to be meeting with Dr Rana McKay who's an associate professor at the University of California San Diego. I got to know Dr McKa...

Spontaneous Cancer Regression Extremely Rare
https://www.medscape.com/viewarticle/985189

Dec 7th, 2022 - Spontaneous regression of solid tumors in the absence of anticancer treatment has been known to occur, but it is extremely rare, a new study confirms. After pooling placebo response rates from 45 cancer drug trials in advanced solid tumors, researchers found a complete response of 0% and a partial response of 1%. "Now we can answer our patients," tweeted lead investigator Bishal Gyawali, MD, Ph...

Novel DCVax-L Vaccine Extends Survival in Glioblastoma
https://www.medscape.com/viewarticle/985104

Dec 6th, 2022 - An investigational vaccine has significantly extended survival in patients with newly diagnosed as well as recurrent glioblastoma, according to new findings from a phase 3 trial (NCT00045968).   "Immunotherapy is a very promising approach for treating cancer, and the final results of this phase 3 trial, now unblinded and published, offer fresh hope to patients battling with glioblastoma," comme...

Merck Could Keep Its Patent Edge by Shifting Keytruda Cancer Drug to a Simple Shot
https://www.medscape.com/viewarticle/984906

Dec 5th, 2022 - (Reuters) - U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling drug from competition expected as soon as 2028. For years Merck has relied on Keytruda to fuel its growth. The treatment, approved in 2014, harnesses the body's own immune system to fight cancers wit...

ICIs Increase Risk for Brain Injury From Cranial Radiotherapy
https://www.medscape.com/viewarticle/984895

Dec 1st, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Immune checkpoint inhibitors increase the risk for brain injury among patients with lung cancer who receive cranial radiotherapy to treat brain metastases, especially when immunotherapy is used within 3 months of radiotherapy. Why This Matters Cranial radiotherapy...

With Type 1 Diabetes Delay Possible, Focus Now on Screening
https://www.medscape.com/viewarticle/984748

Nov 30th, 2022 - The recent approval of teplizumab-mzwv (Tzield, Provention Bio) for the delay of type 1 diabetes by the US Food and Drug Administration is expected to advance efforts to increase screening to cost-effectively identify those at risk for the condition who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved November 17 as the first disease-modifying therap...

Atezolizumab (Tecentriq) Bladder Cancer Indication Withdrawn in US
https://www.medscape.com/viewarticle/984722

Nov 29th, 2022 - Atezolizumab (Tecentriq) is no longer approved in the United States for use in certain patients with bladder or urinary tract cancer. The drug is an anti-PD-L1 inhibitor immunotherapy, and continues to be approved for use in lung and liver cancer and melanoma. The manufacturer, Genentech, announced that it was voluntarily withdrawing the US indication for atezolizumab that covered its use in  a...

Stool Transplants May Boost Immunotherapy Success in Melanoma
https://www.medscape.com/viewarticle/984710

Nov 29th, 2022 - In advanced and metastatic melanoma patients, fecal microbiota transplant (FMT) from healthy donors in advance of anti–PD-1 immunotherapy led to a 75% clinical benefit rate, defined as complete response, partial response, or stable disease that lasted 6 months or longer. The results come from a small, single arm phase 1 study whose primary endpoint was safety. "We know that the gut microbiome h...

Discontinuing Immunotherapy: Is the Infusion Bag Half Empty or Half Full?
https://www.medscape.com/viewarticle/984085

Nov 21st, 2022 - It's a "champagne problem" many of us have encountered over the past few years in the clinic. A patient with advanced non–small cell lung cancer (NSCLC) is fortunate enough to continue to do well for 2 years on ongoing pembrolizumab or perhaps pemetrexed and pembrolizumab as maintenance therapy. The latest CT shows a residual but far smaller primary tumor than what she started with. In this ins...

Immunotherapy and You: Understanding the PD-L1 Blockade
https://www.onclive.com/view/immunotherapy-and-you-understanding-the-pd-l1-blockade

Nov 18th, 2022 - In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, of the Division of Gynecologic Oncology, Allegheny Health Network, and assistant professor of OBGYN at Drexel University, and Ali Amjad, MD, medical hematologic oncologist, Allegheny Health Network, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agen...

Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms?
https://www.medscape.com/viewarticle/984335

Nov 18th, 2022 - The asthma medication tezepelumab, added to subcutaneous immunotherapy treatment (SCIT), may provide better, longer-lasting symptom relief than allergy shots alone for patients with allergic rhinitis caused by cat allergens, according to results of a phase 1/2 clinical trial. "One year of allergen immunotherapy [AIT] combined with tezepelumab was significantly more effective than SCIT alone in ...

Novel Vaccine Approach Halts Disease After 23 Years of Breast Cancer 
https://www.medscape.com/viewarticle/984217

Nov 17th, 2022 - A woman who had breast cancer for 23 years, and who had gone through 12 different lines of therapy, has shown a dramatic response to a novel cancer vaccine in a clinical trial. A recent 6-month follow-up showed no evidence of new or recurrent disease, and scans showed regression of a distant bulky left adrenal metastasis, as well as at other sites. A small site of residual hypermetabolism remai...

Long-term Survival Data With Immunotherapy in Gynecologic Cancers
https://www.onclive.com/view/long-term-survival-data-with-immunotherapy-in-gynecologic-cancers

Nov 16th, 2022 - In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, of the Division of Gynecologic Oncology, Allegheny Health Network, and assistant professor of OBGYN at Drexel University, and Ali Amjad, MD, medical hematologic oncologist, Allegheny Health Network, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers. Nakayama...

Small Cell Lung Cancer: What Are the First-line and Second-line Treatment Options?
https://www.medscape.com/viewarticle/969536

Nov 15th, 2022 - This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jacob Sands, MD: Hello. I'm Dr Jacob Sands, a thoracic medical oncologist at Dana-Farber Cancer Institute where I lead our small cell lung cancer program. Welcome to Medscape's InDiscussion series on lung cancer. To...

Annual Lung Cancer Screening Rates Still Low: Lots of Reasons Why
https://www.medscape.com/viewarticle/984076

Nov 15th, 2022 - Fewer than 6% of high-risk smokers undergo an annual lung cancer screening test as is recommended by health authorities, even though the test can detect early lung cancer when it is still curable, according to a new report from the American Lung Association. It begs the question: Why are the screening rates so dismally low? "There are a lot of reasons why," the report's lead author, Zach Jump, ...

Epicutaneous Immunotherapy Promising in Young Peanut-Allergic Children
https://www.medscape.com/viewarticle/984077

Nov 15th, 2022 - LOUISVILLE, Kentucky — A 12-month course of epicutaneous immunotherapy with a patch that contained 250 μg of peanut protein was associated with significant desensitization to peanut protein compared with placebo in peanut-allergic children aged 1 to 3 years, according to results from the phase 3 EPITOPE study. Study author Matthew Greenhawt, MD, professor of pediatrics-allergy/immunology at the...

Peanut-Allergic Toddlers Also Benefit From Oral Immunotherapy With Palforzia
https://www.medscape.com/viewarticle/984053

Nov 14th, 2022 - LOUISVILLE, Kentucky — Compared with placebo, treatment with peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia) significantly improved the amount of peanut protein that could be tolerated by peanut-allergic children between 1-3 years of age after 12 months of treatment with the oral immunotherapy, according to results of a randomized clinical trial. The phase 3 POSEIDON study also showe...

Early Monitoring Helps Curb GI Toxicity From Immunotherapy
https://www.medscape.com/viewarticle/983924

Nov 11th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway A quality improvement program at MD Anderson Cancer Center, Houston, Texas, substantially improved outcomes from severe immune-mediated diarrhea and colitis. Why This Matters Immune-mediated diarrhea and colitis is a common and vexing complication of immune checkp...